- 全部删除
 
您的购物车当前为空
MK-0626是一种可口服的二肽基肽酶IV(DPP-4)抑制剂,通过增强AMPK活性,减轻肝脏脂肪变性和蓄积。MK-0626通过恢复GLP-1R的表达减轻了TAC诱导的糖尿病胰岛损伤。MK-0626能够通过增加循环内皮祖细胞的数量和内皮型一氧化氮合酶的表达,促进新血管生成。


为众多的药物研发团队赋能,
让新药发现更简单!
MK-0626是一种可口服的二肽基肽酶IV(DPP-4)抑制剂,通过增强AMPK活性,减轻肝脏脂肪变性和蓄积。MK-0626通过恢复GLP-1R的表达减轻了TAC诱导的糖尿病胰岛损伤。MK-0626能够通过增加循环内皮祖细胞的数量和内皮型一氧化氮合酶的表达,促进新血管生成。
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 1 mg | ¥ 7,620  | In stock | |
| 5 mg | ¥ 15,200  | In stock | |
| 10 mg | ¥ 19,800  | In stock | |
| 25 mg | ¥ 30,570  | In stock | |
| 50 mg | ¥ 42,800  | In stock | 
MK-0626 相关产品
| 产品描述 | MK-0626 is an orally available dipeptidyl peptidase IV (DPP-4) inhibitor that attenuates hepatic steatosis and accumulation by enhancing AMPK activity.MK-0626 attenuates TAC-induced diabetic pancreatic islet injury by restoring the expression of GLP-1R.MK-0626 is able to increase circulating endothelial progenitor cell numbers and endothelial-type nitric oxide synthase expression by promoting neoangiogenesis.  | 
| 体内活性 | 方法: MK-0626(1.5和3mg/kg,口服)治疗ob/ob 小鼠,采集血样,进行全肝切除术。  | 
| 别名 | MK0626 | 
| 分子量 | 442.46 | 
| 分子式 | C22H24F2N6O2 | 
| CAS No. | 690257-74-0 | 
| Smiles | [C@H]([C@@H](C(=O)N1CC(F)(F)CC1)N)(C(N(C)C)=O)C2=CC=C(C=C2)C3=CN4C(C=C3)=NC=N4 | 
| 存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | 
评论内容